Another class of growth hormone (GH) secretagogues has been discovered by altering the backbone structure ofa flexible linear GH-releasing peptide (GHRP). In vitro and in vivo characterization confirms these GH secretagogues as the most potent and smallest (Mr < 500) reported. Anabolic efficacy is demonstrated in rodents with intermittent delivery. A convergent model of the bioactive conformation of GHRPs is developed and is supported by the NMR structure of a highly potent cyclic analog of GHRP-2. The model and functional data provide a logical framework for the further design of low-molecular weight secretagogues and illustrate the utility of an interdisciplinary approach to elucidating potential bound-state conformations of flexible peptide ligands.
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Growth hormone (GH) regulates optimal statural growth in children and body composition in adults. The pulsatile release of GH from the pituitary somatotrophs is controlled by a complex endocrine interaction involving hypothalamic neuronal hormones that induce (via GH-releasing hormone, GHRH) or suppress (via somatostatin) GH secretion. Discovered before GHRH, the GH-releasing peptides (GHRPs) were derived by systematically optimizing the GH-releasing activities of Met-enkephalin (1, 2) . The GHRPs and GHRH directly stimulate GH secretion by the pituitary (3, 4) via different mechanisms (5, 6) , and a synergistic response is observed when the two are co-administered (7, 8) . More potent GH secretagogues have subsequently been developed by further modification of the GHRPs (9) , and recently a nonpeptidyl lead series was identified by screening (10) . Despite considerable interest in these molecules as a potential alternative to injectable recombinant human GH therapy, their clinical use is currently limited by low oral bioavailability and a poor understanding of the pharmacodynamic profile required for optimal efficacy. Neither an endogenous counterpart nor its receptors have been reported.
The intrinsic (in vitro) secretagogue activity of the prototype peptide GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) results primarily from the charged side chain of the N-terminal histidine and the central aromatic residues; the C-terminal lysine residue, although not absolutely required for in vitro activity, appears to contribute significantly to in vivo potency (11) . Activity is enhanced when DTrp2 is replaced by D-2-(2-naphthyl)alanine (D2Nal) , and the N-terminal charge is delivered by the stereochemically analogous backbone nitrogen of D-alanine (GHRP-2, DAla-D2Nal-Ala-Trp-DPhe-Lys-NH2) (9, 12) . No potent cyclic analogs of GHRP have been reported, and little progress has been made in determining the topographical requirements for GHRP bioactivity, thus frustrating efforts to design secretagogues with improved pharmacological properties.
We describe here a strategy that has produced a highly active cyclic analog of GHRP-2 that is structured in water. We have also determined a minimal set of functional interactions that are actually required for GHRP activity, leading to the development of a highly potent secretagogue with a molecular mass <500 Da. Potential regimens for extended treatment with these molecules are examined.
MATERIALS AND METHODS
Peptide Synthesis. Synthesis of peptides was done by solidphase peptide synthesis using either t-butoxycarbonyl (Boc) or 9-fluorenylmethoxycarbonyl (Fmoc) protocols (13) using commercially available reagents. C-terminal hydroxymethyl derivatives were prepared by cleaving the N-Boc amino acid from Wang resin with excess lithium borohydride in tetrahydrofuran followed by treatment with trifluoroacetic acid. The purity and identity of all compounds were established by analytical reverse-phase liquid chromatography (methanol/water/trifluoroacetic acid gradient), electrospray mass spectrometry (MS), highresolution fast atom bombardment MS, and either amino acid analysis or 1H and 13C NMR, as appropriate.
NMR Structure Determination. Peptide (3.4 mg) was dissolved in 500 ,ul of 90% H20/10% 2H20/50 mM sodium [2H3]acetate, pH 4.5. All NMR spectra were acquired at 7°C on a Bruker AMX500 spectrometer. Standard spectra were recorded including correlated (COSY), total correlated (TOCSY) [isotropic mixing sequence (14) applied for 70 ms], and nuclear Overhauser enhancement (NOESY) spectroscopies (mixing time of 300 ms). Spectra were processed and analyzed using FELIX (Biosym Technologies, San Diego). Nuclear Overhauser effect cross peaks were characterized as strong, medium, or weak, corresponding to upper bound distance restraints of 3.0, 4.0, and 5.0 A, respectively; pseudoatom corrections were added when necessary (15 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
applied to align the side-chain rings (ro = 1.0 A; k = 10.0 kcal/A2) and backbone a carbons (ro = 1.5 A) of the aromatic residues. No attempt was made to align the N or C termini. Calculations were performed with DISCOVER using the AMBER force field as described above. Systematic conformation searching was performed with the CSEARCH module of SYBYL (Tripos Associates, St. Louis) using 10°-angle increments. Apparent local minima from this search were minimized using MM2 (19) , and redundant structures were removed.
Biological Assays. In vitro activity was assessed by measuring GH release from primary pituitary cell cultures. Anterior pituitaries from 200-to 220-g female Sprague-Dawley (SD) rats were enzymatically dispersed, and the cells were plated at 100,000 cells per ml in incubation/challenge medium. Cells were challenged with test compounds after 3 days at 37°C in 5% CO2. Compounds were evaluated at six concentrations with six wells per concentration. Three to five EC50 values from independent experiments were used to derive the mean and SEM. In vivo potency was established in anesthetized female SD rats using the protocol described by Sartor et al. (20) . Anabolic efficacy was assessed using 150-day-old female SD rats. Compounds (100 ,ug per rat per day) were administered either continuously by s.c. pump infusion or twice daily by s.c. injection for a total of 2 weeks. Weight gain was monitored daily. Animal procedures and protocols were approved by the Genentech Institutional Animal Care and Use Committee.
Hormone Assays. The concentrations of rat GH in medium and serum were determined by using a specific two-site rat GH ELISA. The intraassay and interassay variations were <6 and <10%, respectively. Luteinizing hormone, follicle-releasing hormone, thyroid-stimulating hormone, and prolactin levels were determined by using commercially available RIA kits (Amersham); adrenocorticotropin levels were determined using an RIA kit from ICN.
RESULTS
Cyclic Peptides. Starting from GHRP-2, the side chain of an N-terminal D-amino acid (replacing DAla1) was linked to the side chain of an amino acid inserted between DPhe5 and Lys6, thus enclosing the critical aromatic residues within a cyclic backbone. The activities of this cyclic series are summarized in Table 1 . The most potent cyclic GHRP analog reported, la has -10-fold greater activity than GHRP-6 in vitro and comparable acute efficacy in vivo. The activity of this series is highly sensitive to the composition of the linkage amide. Transposing the amide carbonyl to the N-terminal side of the -NH (lb) reduces activity 100-fold. An even greater reduction is seen when the amide bond of la is shifted toward the N terminus (1c). Deleting a methylene group on either side of the amide bond (ld, le) likewise produces decreased activity. These results suggest that la supports a specific, productive conformation of the aromatic core that is not readily accessible to the other molecules.
NMR studies indicate that la is structured in water. The final set of refined structures contain no distance violations >0.1 A and no dihedral violations. (NMR restraints and structures for la are available on written request.) As shown in Fig. 1 , the D2Nal-Ala-Trp-DPhe fragment adopts a compact conformation with nested hairpin turns initiated at DLyst and Ala3. The cyclic portion of this peptide is well defined (average pairwise root-mean-square deviation = 0.52 + 0.21 A), and the average pairwise deviation of the D2Nal-Ala-Trp-DPhe backbone is 0.27 ± 0.16 A. The C-terminal lysine is disordered and is not shown. On either side of the DLys1-Glu6 amide bond, the cyclization linkage makes a sharp 900 bend. Modeling studies suggest that the linkages of the less active analogs lb-le do not readily adopt a similar conformation. active tetrapeptide Tyr-DTrp-DTrp-Phe-NH2 to a progenitor of GHRP-6 by inserting an alanine between the central DTrp residues and inverting the stereochemistry of the two Cterminal amino acids. The activity of the resulting peptide, Tyr-DTrp-Ala-Trp-DPhe-NH2, was subsequently enhanced by replacing the N-terminal tyrosine with histidine and by appending a lysine to the C terminus to produce GHRP-6, the first of this series to show in vivo activity (11) . The structural implications of these manipulations were intriguing: if the initial tetrapeptide and GHRP-6 act by a common mechanism (presumably by binding to a common site), the bioactive conformations of these molecules should share a similar three-dimensional presentation of the key aromatic residues.
We therefore conducted an analogous evolution of the shorter tetrapeptide series starting from Tyr-DTrp-DTrp-Phe-NH2. Key intermediates in the sequential optimizations of both the longer (2a-e) and shorter (3a-f) series are shown in Table  2 . Replacing Tyr1 of 3a by histidine (3b) did not significantly improve activity, although adding a C-terminal lysine (3c) produced a molecule that was only 4-fold less potent than GHRP-6 (2c). Substituting D2Nal for DTrp2 (3d) and aminovaleric acid for His1 (3e) further increased activity, similar to the trend observed in 2d and 2e. The activity of 3e was further Proc. Natl. Acad. Sci. USA 92 (1995) Proc. Natl. Acad. Sci. USA 92 (1995) 11167 (3f) which demonstrated comparable in vivo potency to 2e (ED50 = 2.6 vs. 1.5 gg, respectively) and was chosen as a lead for medicinal chemistry. Activity was dramatically improved by the incorporation of isonipecotic acid (inip) at the N terminus (4a , Table 3 ), resulting in a compound over 10-fold more potent in vitro than 3f and 30-fold more potent than GHRP-6.
Mechanistic Characterization. This class of secretagogues, represented by 4a, shares the mechanistic profile characteristic of GHRP-6 and related molecules (2, 5, 8) . Repeated exposure of 4a induces homologous desensitization of GH release from pituitary cells ( Fig. 2A) , although responsiveness to GHRH is maintained. While a combination of GHRP-6 and 4a does not increase maximal GH release, GHRH in combination with either 4a or GHRP-6 enhances GH secretion (Fig. 2B) , indicating that 4a and GHRH act via different sites. Somatostatin, which suppresses GHRP-stimulated GH release, has a similar effect on 4a (Fig. 2C) . Compound 4a releases GH in a dose-dependent manner with no significant release of luteinizing hormone, follicle-stimulating hormone, adrenocorticotropic hormone, or thyrotropic hormone. A 1.5-fold increase in prolactin was seen, which is also seen with GHRP-6 incubation. Similar results were found for la (KA.E., unpublished data), further supporting the hypothesis that la, 4a, and GHRP-6 interact at a common site.
Consensus Structures. Each ensemble dynamics trajectory converged to one of the two consensus alignments illustrated in Fig. 3 A and Fig. 3B is remarkably similar to the conformation observed in the NMR structure of la: the average deviation in this region between the NMR and dynamics structures is 0.87 ± 0.23 A. The principal discrepancy between the two, the Xi angle of D2Nal2, is resolved if the side chain of this residue in the tetrapeptide adopts an alternate, low-energy rotamer that overlaps well with the NMR structure of la.
Systematic Reduction of 4a. We next investigated the minimal functional pharmacophore of these compounds with the aim of reducing their molecular weight and complexity. Table  3 shows the sequential reduction of 4a to the small peptidomimetic 4g. In contrast to the GHRP-6 series (2a-2e), the C-terminal lysine of 4a can be removed while retaining in vivo potency (4c). Replacing the third aromatic ring with an alkyl amine (4d) greatly simplifies the C terminus, but a drop in intrinsic activity is observed. Potency is restored by Nmethylating D2Nal2 (4e); this modification has little effect on other molecules within this series. The hydroxymethyl derivative 4f retains high in vitro potency, although most other modifications that removed the amine from the C terminus of 4d greatly reduced activity. Substituting an indole for the second naphthalene ring generates the lowest-Mr GH secretagogue reported with significant in vivo activity (4g).
A systematic search over all internal torsions of 4f and 4g confirms that these molecules share a minimum-energy backbone conformation that is identical to the consensus alignment of 4a shown in Fig. 3B . We believe that this conformation, shown in Fig. 3C Fig. 1 ; the C-terminal lysine is omitted for clarity. (B) Alternate consensus model of la and 4a in which D2Nal2 is projected on the opposite face of the peptide. This conformation is consistent with the NMR structure of la. (C) Minimum-energy structure of 4f from systematic conformational searching. This simple structure, in which the two aromatic rings are presented on opposite faces of a central amide bond, represents a minimal three-dimensional pharmacophore for the GHRPs. pharmacophore of GHRPs, although the biologically relevant rotamers of the aromatic side chains have yet to be determined.
In Vivo Profi'les. Fig. 4 i.v. dose-response curves for these structurally distinct compounds are consistent with a common, specific site of action. The pseudo-pentapeptide 4b is the most potent GHRP-like compound ever reported in vivo. However, as evidenced by the in vitro and in vivo data for the pairs 4a/4b, 4d/4e, and 4f/4g shown in Table 3 , small changes in structure can have large and differential effects on the two measures of activity. Indeed, only a modest correlation is observed between the in vitro and in vivo assay results for a large sample of diverse GH secretagogues (Fig. 5) .
The anabolic effects of continuous vs. intermittent administration of 4a are contrasted in Fig. 6 . At 150 days, the normal growth rate of female SD rats (5 g per day) has slowed below 2 g per week, and the anabolic effect of the secretagogues is significant. Weight gain was observed in these animals given twice daily injections of 4a. This increase, evenly distributed over the organs and tissues, is consistent with the results seen with GH treatment in this model. By contrast, the same total daily dose given as a continuous infusion induced tachyphlaxis after an initial increase in growth velocity (4a is stable in a minipump under these conditions). This effect is reminiscent of the functional antagonism induced by super-agonists to other endocrine receptors and has not previously been reported for GH secretagogue-induced growth responses.
DISCUSSION
In exploring the structural requirements for GHRP activity, we have discovered a structured, cyclic analog with significant in vivo potency (la), a peptide (4a) that demonstrates anabolic efficacy with intermittent exposure, and a low-molecular weight peptidomimetic (4g) that retains the in vitro and in vivo activity of GHRP-6. The discovery of la, combined with a transfer of the aromatic residues onto a more compact peptide backbone, have enabled the derivation of a convergent structural model. The consensus structures from ensemble dynamics did not incorporate any restraints other than the intermolecular tethering potentials. Despite the considerable flexibility of the initial molecules, it is encouraging that only two possible alignments of the aromatic residues were ultimately identified, one of which was supported by the NMR structure of la. These findings suggest that the conformational requirements for activity in a flexible linear molecule can be mapped by modifying the backbone chirality and the spacing between functionally important side chains. The ultimate precision of the resulting model is enhanced when structurally diverse cyclic analogs are included in the ensemble.
The high in vivo activity of 4g indicates that only a subset of the aromatic core is required for full secretagogue function. In vivo ED50 (9g) These results are consistent with the activity of the benzolactam secretagogue L-692,429, which can be similarly construed as presenting a subset of the GHRP-6 functionality. Further constraint of 4g should distinguish among the possible sidechain conformations, providing further refinement of this model for the design of other minimal GH secretagogues.
